Brief: Targovax: Encouraging Survival Data For Oncos-102 In Mesothelioma

Circio Holding ASA

24/11/2020 06:05

Nov 24 (Reuters) - Targovax ASA  TRVX.OL :
    * TARGOVAX DEMONSTRATES ENCOURAGING SURVIVAL DATA FOR ONCOS-102 IN MESOTHELIOMA
    * AN 18-MONTH ANALYSIS SHOWS THAT MEDIAN OVERALL SURVIVAL (MOS) WILL BE AT LEAST 18.2 MONTHS
FOR
FIRST-LINE PATIENTS RECEIVING ONCOS-102 PLUS CHEMOTHERAPY, COMPARED TO MOS OF 14.2 MONTHS OR
LESS IN CHEMOTHERAPY-ONLY CONTROL GROUP
    * ONCOS-102-TREATED PATIENTS SHOW BROAD AND POWERFUL IMMUNE ACTIVATION, ASSOCIATED WITH
BETTER
SURVIVAL OUTCOME
    * BASED ON CURRENT SURVIVAL DATA MOS WILL BE 18.2 MONTHS OR LONGER
    * NEXT SURVIVAL ANALYSIS IS PLANNED IN FIRST HALF OF 2021

Source text for Eikon:  ID:nWkr8tg98s 
Further company coverage:  TRVX.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))